Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumacaftor/ivacaftor in children aged 2 to 5 years with cystic fibrosis homozygous for F508del
2017-003761-99Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lumacaftor and ivacaftor in cystic fibrosis (CF) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute change from baseline in MRI global chest score. Started Feb 2018; status: completed.
02
Drugs
lumacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2017-003761-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003761-99.